McGibbon A, Adams L, Ingersoll K, et al. Glycemic management in adults with type 1 diabetes. Can J Diabetes. 2018;42(Suppl 1):S80–7.

Article  PubMed  Google Scholar 

Lipscombe L, Butalia S, Dasgupta K, et al. Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update. Can J Diabetes. 2020;44(7):575–91.

Article  PubMed  Google Scholar 

Rosenstock J, Juneja R, Beals JM, et al. The basis for weekly insulin therapy: evolving evidence with insulin icodec and insulin efsitora alfa. Endocr Rev. 2024;45(3):379–413.

Article  PubMed  PubMed Central  Google Scholar 

Shetty S, Suvarna R. Efficacy and safety of once-weekly insulin icodec in type 2 diabetes: a meta-analysis of ONWARDS phase 3 randomized controlled trials. Diabetes Obes Metab. 2024;26(3):1069–81.

Article  CAS  PubMed  Google Scholar 

Novo Nordisk A/S. Awiqli (insulin icodec) 700 units/mL solution for injection in pre-filled pen: EU summary of product characteristics. 2024. https://www.ema.europa.eu/en/documents/product-information/awiqli-epar-product-information_en.pdf. Accessed 20 June 2024.

Novo Nordisk Canada Inc. Awiqli®—world’s first once-weekly basal insulin—now available in Canada [media release]. 14 Jun 2024. https://www.novonordisk.ca/content/dam/nncorp/ca/en/press-releases/2024/awiqli-launch-press-release-june-14-2024.pdf.

Health Canada. Regulatory decision summary for Awiqli. 2024. https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1711383693011. Accessed 20 June 2024.

BioSpace. Novo Nordisk’s once-weekly insulin loses FDA Adcomm vote for type 1 diabetes [media release]. 28 May 2024. https://www.biospace.com/article/novo-nordisk-s-once-weekly-insulin-loses-fda-adcomm-vote-for-type-1-diabetes/.

Nishimura E, Pridal L, Glendorf T, et al. Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing. BMJ Open Diabetes Res Care. 2021;9(1):1–10.

Article  Google Scholar 

Hövelmann U, Engberg S, Heise T, et al. Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes. Diabetes Obes Metab. 2024;26(5):1941–9.

Article  PubMed  Google Scholar 

Pieber TR, Asong M, Fluhr G, et al. Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 2 diabetes. Diabetes Obes Metab. 2023;25(12):3716–23.

Article  CAS  PubMed  Google Scholar 

Plum-Mörschel L, Andersen LR, Hansen S, et al. Pharmacokinetic and pharmacodynamic characteristics of insulin icodec after subcutaneous administration in the thigh, abdomen or upper arm in individuals with type 2 diabetes mellitus. Clin Drug Investig. 2023;43(2):119–27.

Article  PubMed  PubMed Central  Google Scholar 

Haahr H, Cieslarova B, Donatsky AM, et al. The effect of various degrees of hepatic impairment on the pharmacokinetic characteristics of once-weekly insulin icodec [abstract no. 809-P]. Diabetes. 2023;72(Suppl_1):3.

Google Scholar 

Russell-Jones D, Babazono T, Cailleteau R, et al. Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial. Lancet. 2023;402(10413):1636–47.

Article  CAS  PubMed  Google Scholar 

Rosenstock J, Bain SC, Gowda A, et al. Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. N Engl J Med. 2023;389(4):297–308.

Article  CAS  PubMed  Google Scholar 

Lingvay I, Asong M, Desouza C, et al. Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive type 2 diabetes: the ONWARDS 3 randomized clinical trial. JAMA. 2023;330(3):228–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bajaj HS, Aberle J, Davies M, et al. Once-weekly insulin icodec with dosing guide app versus once-daily basal insulin analogues in insulin-naive type 2 diabetes (ONWARDS 5): a randomized trial. Ann Intern Med. 2023;176(11):1476–85.

Article  PubMed  Google Scholar 

Rosenstock J, Bajaj HS, Janež A, et al. Once-weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med. 2020;383(22):2107–16.

Article  CAS  PubMed  Google Scholar 

Lingvay I, Buse JB, Franek E, et al. A randomized, open-label comparison of once-weekly insulin icodec titration strategies versus once-daily insulin glargine U100. Diabetes Care. 2021;44(7):1595–603.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Philis-Tsimikas A, Asong M, Franek E, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol. 2023;11(6):414–25.

Article  CAS  PubMed  Google Scholar 

Mathieu C, Ásbjörnsdóttir B, Bajaj HS, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet. 2023;401(10392):1929–40.

Article  CAS  PubMed  Google Scholar 

Bajaj HS, Bergenstal RM, Christoffersen A, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care. 2021;44(7):1586–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Novo Nordisk Canada, Inc. AWIQLI® insulin icodec injection product monograph. 2024. https://pdf.hres.ca/dpd_pm/00074917.PDF. Accessed 30 May 2024.